imiquimod has been researched along with vorinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Acikelli, AH; Andrioff, S; D'Souza, F; Dammann, P; Demmig, R; Díaz-Carballo, D; Erwes, J; Grandi, N; Homp, E; Klein, D; Klein, J; Malak, S; Menze, S; Nasreen, A; Noa-Bolaño, A; Ochsenfarth, C; Pano, E; Saka, S; Schröer, K; Strumberg, D; Tannapfel, A; Teipel, M; Tramontano, E | 1 |
2 other study(ies) available for imiquimod and vorinostat
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Depsipeptides; Endogenous Retroviruses; Female; Histone Deacetylase Inhibitors; Humans; Imiquimod; Immunity, Innate; Mice, Nude; Ovarian Neoplasms; Pteridines; Signal Transduction; Toll-Like Receptor 7; Tumor Cells, Cultured; Viral Envelope Proteins; Virus Activation; Vorinostat; Xenograft Model Antitumor Assays | 2021 |